Moderna Procures $1.5B Loan To Grow Its Pipeline Beyond Vaccines
Synopsis
The company is now eyeing 10% revenue growth in 2026.
Vaccine maker Moderna (MRNA) said on Thursday that it has secured a $1.5 billion, five-year credit facility from Ares Management Credit Funds as it seeks to pivot into oncology and rare-disease therapeutics.
The company is now eyeing 10% revenue growth in 2026. It said that the five-year term loan facility will strengthen its balance sheet and provide increased flexibility going forward.
The initial tranche of $600 million, of three tranches, will be drawn upfront, the company said, followed by the option to avail $400 million through November 2027. The company can also draw another $500 million through November 2028 under the credit facility.
MRNA shares traded 2% higher in the pre-market session at the time of writing.
Get updates to this developing story directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.